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Chitooligosaccharide (COS) is derived from the chemical and enzymatic hydrolysis of chitosan and has been reported to have 
potent antitumor activity. Our study investigated the effects of five chitooligomers ranging from the dimer form to the hexamer 
form (chitobiose, chitotriose, chitotetraose, chitopentaose, chitohexaose) on the expression of cyclin D1, bcl-2 and bcl-xl mRNA 
in A549 cells using reverse transcription quantitative real-time PCR. We demonstrated that, of the five chitooligomers used, chi-
tohexaose (COS6) had the most potent inhibitory effect on A549 cell proliferation. COS6 also significantly down regulated cyclin 
D1 and bcl-xl mRNA expression levels. Our data suggested that COS6 exerts its antitumor activity by two different mechanisms: 
(1) COS6-mediated inhibition of Cyclin D1 levels leads to suppression of tumor cell proliferation; and (2) COS6-mediated 
down-regulation of the pro-survival protein, Bcl-xl, promotes the apoptosis of tumor cells. 
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Chitooligosaccharide (COS) is derived from the chemical or 
enzymatic decomposition of chitin or chitosan [1]. COS has 
been reported to have a lower molecular weight and a 
higher water solubility and activity when compared with 
chitosan. A number of studies have suggested that COS has 
antimicrobial [2], antibacterial [3] and antioxidant proper-
ties [4,5], and has also been shown to play an important role 
in antitumor responses [6,7]. 
The antitumor activity of COS is likely influenced by its 
chemical structure, molecular size, and strong electric 
charge [6–8]. Administration of N-acetylchitohexaose 
(NACOS-6) resulted in a significant increase in the candi-
dacidal activity of macrophages and T lymphocytes in the 
early phase of tumor development [8] and COS was sug-
gested to play a role in the induction of apoptosis of carci- 
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noma cells via up-regulation of Bax [9]. The chitohexamer 
form was shown to down-regulate VEGF and uPA mRNA 
expression levels in ECV304 cells [10], and to inhibit tu-
mor growth and metastasis by up-regulation of p21 and 
MMP-9, and down-regulation of PCNA, cyclin A and cdk-2 
[11]. However, the effects of different forms of COS on 
the expression levels of cyclin D1 and the pro-survival 
proteins bcl-2 and bcl-xl are unknown. In this study, we 
investigated the role of five different fractions [chitobiose 
(COS2), chitotriose (COS3), chitotetraose (COS4), chito-
pentaose (COS5), chitohexaose (COS6)] on the regulation 
of cyclin D1, bcl-2 and bcl-xl mRNA levels in A549 cells. 
We demonstrated that COS6 exhibited the most potent 
inhibitory activity on A549 cell proliferation by down- 
regulation of cyclin D1 mRNA. Treatment of A549 cells 
with COS6 also resulted in suppression of bcl-xl mRNA 
expression levels. 
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1  Materials and methods 
(i) Materials.  RPMI 1640 medium and fetal calf serum 
(FCS) was purchased from GIBCO, USA. Chitooligomers 
(chitobiose, chitotriose, chitotetraose, chitopentaose and 
chitohexaose) were from Dalian GlycoBio Co. Ltd. (China). 
Trizol reagent, M-MLV Reverse Transcriptase and the 
Platinum SYBR Green qPCR SuperMix-UDG kit were all 
from Invitrogen (Carlsbad, CA, USA). All primers were made 
by Sangon (Shanghai, China). 
(ii) Cell culture.  The A549 human lung carcinoma cell 
line was cultured in RPMI 1640 medium supplemented with 
10% (v/v) FCS, and maintained at 37°C/5% CO2. Cells were 
treated with different chitooligomers (100 μg/mL) after se-
rum starvation for 12 h. 
(iii) Cell proliferation assay.  The effect of the different 
COS fractions on proliferation of A549 cells was deter-
mined by the MTT assay. Cells cultured in 96-well plates 
were treated with different COS fractions (100 μg/mL) for 
48 h at 37°C. A 20 μL volume of MTT (5 mg/mL; Sigma) 
was added to each well and cells were incubated for another 
4 h before adding 120 μL DMSO to each well to dissolve 
the blue crystals. The absorbance was read at 490 nm using 
an MK3 microplate reader (Thermo Electron Corporation, 
Shanghai, China).  
(iv) RNA extraction and reverse transcription.  A549 
cells were treated with chitooligomers (100 μg/mL) for 48 
h, and total RNA was extracted using TRIzol reagent ac-
cording to the manufacturer’s instructions. Total RNA (1 
μg) was reverse transcribed using 20 U of M-MLV Reverse 
Transcriptase and Oligo(dT)18 primers according to the 
manufacturer’s instructions (M-MLV First Strand Kit; Invi-
trogen). The reaction was incubated at 37°C for 50 min and 
then 70°C for 15 min. 
(v) Quantitative real-time PCR (qPCR).  The amplifica-
tion of cDNA amplification was performed by qPCR using 
the Platinum SYBR Green qPCR SuperMix-UDG kit ac-
cording to the manufacturer’s instructions. Briefly, a mix of 
the following reaction components was prepared: 1 μL 
cDNA; 12.5 μL 2× Platinum SYBR Green qPCR Super-
Mix-UDG; 2.5 μL (0.2 μM) of each primer and 6.5 μL wa-
ter. The forward and reverse primer sequences for each gene  
product are listed in Table 1. Data were acquired with the 
Chromo4 Real-Time detector (MJ Research). Gene expres-
sion was normalized to the endogenous expression of 
β-actin, which was determined not to have significantly 
changed in the different experiments. The PCR cycling 
conditions involved an initial denaturation step at 95°C for 
10 min, followed by 45 cycles at 95°C for 15 s and 60°C for 
60 s, then completed with a melting curve from 55–95°C 
with a heating rate of 1°C/s and continuous fluorescence 
measurement. For analysis, a standard curve was con-
structed from β-actin amplification in two serial 10-fold 
dilutions of cDNA stock from untreated A549 cells. The 
target cDNA levels in each sample were quantified against a 
standard curve as sample molecule units and were normal-
ized to the sample β-actin units. The concentration of the 
target gene was expressed as arbitrary units and calculated 
according to the following formula: relative target molecule 
production units = sample target molecule units/sample 
β-actin units. 
(vi) Statistical analysis.  Statistical results were obtained 
using the statistical software SPSS 13.0. The two sample 
t-test was used for statistical analysis. Values of P<0.05 
were considered significant. 
2  Results  
2.1  Effects of different chitooligomers on A549 cell  
proliferation 
We used the MTT assay to analyze the effects of different 
chitooligomers on A549 cell proliferation. Cells were incu-
bated with different chitooligomers [COS2–COS6 (100 
μg/mL)] for 48 h. Control cells were incubated in the ab-
sence of COS. The results were presented as mean ± stan-
dard deviation (SD) of the data from six independent ex-
periments. We demonstrated (Figure 1) a significant inhibi-
tion (n = 6, p<0.05) of proliferation in A549 cells treated 
with COS5 (0.426 ± 0.037) or COS6 (0.376 ± 0.029) when 
compared with untreated control cells (0.574 ± 0.056). 
However, there was no significant change in the prolifera-
tion of A549 cells treated with COS3 (0.536 ± 0.052) or 
COS4 (0.557± 0.084). 
Table 1  Sequences of primers used in qPCR 
Gene Primer sequences 








Reverse: 5′-GGTCGCATT GTGGCCTTT-3′ 
β-actin [14] Forward: 5′-GATGACCCAGATCATGTTTGA-3′ Reverse: 5′-ATGAGGTAGTCAGTCAGGTCC-3′ 
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Figure 1  Effects of chitooligomers on the proliferation of A549 cells (a, 
P < 0.05 vs control, b, P < 0.05 vs. COS6 group). 
2.2  Standard curve for RT-qPCR 
The cDNA template was serially diluted for the standard 
curve to cover the expected concentrations of the target 
genes in all samples. The standard curves were analyzed 
using Real Quant Software. 
2.3  COS6 down-regulated cyclin D1, bcl-xl and bcl-2  
gene expression 
We explored the effects of different COS oligomers on cy-
clin D1, bcl-xl and bcl-2 mRNA levels in A549 cells. Cells 
seeded in 6-well plates were treated with different COS 
oligomers (100 μg/mL) for 48 h and total RNA was pre-
pared. After reverse transcription, cDNA samples were 
subjected to qPCR and results were expressed as the tar-
get:reference ratio of the samples divided by the target: ref-
erence ratio of the control (n = 4). β-actin cDNA was the 
reference gene used in all the experiments. 
We demonstrated that different COS oligomers exerted 
different effects on the expression of cyclin D1, bcl-xl and 
bcl-2 mRNA in A549 cells (Figure 2). We demonstrated 
suppression of bcl-xl mRNA levels in all COS-treated cells 
except the COS4 treated group (COS2: 0.691 ± 0.073; 
COS3: 0.734 ± 0.109; COS4: 0.910 ± 0.110; COS5: 0.589 ± 
0.061; COS6: 0.493 ± 0.042), when compared with un-
treated cells. However, the different COS oligomers did not 
suppress bcl-2 mRNA levels to the same extent as bcl-xl. Of 
all the COS oligomers, COS6 had the strongest suppressive 
activity, and most potently down-regulated cyclin D1 (0.473 
± 0.037) mRNA levels in treated cells when compared with 
control cells (p < 0.05 vs control; Figure 2). We showed a 
significant upregulation in cyclin D1 (1.245 ± 0.118) and 
bcl-2 (1.431 ± 0.096) mRNA levels in COS4 treated cells 
while there was no significant difference in the expression 
levels of these tumor related genes in COS2 and COS5 
treated cells when compared with untreated control cells.  
 
Figure 2  Effect of COS oligomers on the expression of cyclin D1, bcl-xl 
and bcl-2 mRNA in A549 cells, (*, P < 0.05 vs. control). 
3  Discussion 
Malignant transformation of cells in most cancers is char-
acterized by dysregulation of the cell cycle and inhibition of 
cell death. Overexpression of cyclin D1, Bcl-2 or Bcl-xl in a 
number of cancers, including lung, prostate, colorectal, 
breast, cervical, non-Hodgkin’s lymphoma, and both acute 
and chronic leukemia, has been reported to contribute to 
increased resistance to chemotherapy. The cyclin D1 gene, 
located on chromosome 11q13, is an important regulator of 
the cell cycle, which interacts with cyclin dependent kinases 
(CDKs) 4 and 6 to form a CDK 4/6-cyclin D complex. This 
complex phosphorylates the retinoblastoma tumor suppres-
sor gene product (pRb), which forms an inhibitory complex 
with a group of transcription factors known as E2F-DP 
(E2F-1, -2 and -3), and functions to control the G1/S transi-
tion point of the cell cycle [15–17]. Hyperphosphorylation 
of pRb by the Cyclin D1-CDK complex causes a dissocia-
tion of pRb from the E2F inhibitory complexes, permitting 
progression of the cell cycle. Many tumors evade apoptotic 
death signals by expressing anti-apoptotic proteins, such as 
the pro-survival Bcl-2 family members, Bcl-2 and Bcl-xl. 
These proteins are characterized by the presence of four 
Bcl-2 homology (BH) domains, which are required for their 
anti-apoptotic functions. The BH1–BH4 domains mediate 
interactions of these proteins with other protein partners, 
resulting in localization of these proteins at the cytoplasmic 
surfaces of intracellular membranes. The BH1–BH3 do-
mains form a hydrophobic groove, while the N-terminal 
BH4 domain stabilizes this structure from behind the groove 
by burying additional hydrophobic residues, which would 
otherwise be exposed. The hydrophobic groove of Bcl-2 or 
Bcl-xl binds the BH3 α-helix of a pro-apoptotic Bcl-2 fam-
ily member, such as Bax or Bak, inhibiting their binding to 
membranes, and uncovering the C-terminus to trigger the 
apoptotic cascade [18–20]. Overexpression of cyclin D1, 
Bcl-2 and Bcl-xl is strongly associated with tumorigenesis, 
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tumor proliferation, lymph node metastasis and prognosis of 
the cancer. They are valuable molecular markers in the early 
stages of cancer and are important molecular targets in tu-
mor therapy [15,18]. 
In this study, we explored the effect of five COS frac-
tions, ranging from the dimer form to the hexamer form, on 
cyclin D1, bcl-2 and bcl-xl mRNA levels. Our results 
showed that COS6 was the most potent inhibitor of A549 
cellular proliferation. Of all the chitooligomers, COS6 most 
potently down-regulated the mRNA levels of cyclin D1 and 
bcl-xl mRNA. The data suggested that COS6 exerted its 
antitumor activity through inhibition of Cyclin D1 expres-
sion, which resulted in suppression of tumor cell prolifera-
tion, and inhibition of the expression of the pro-survival 
protein, Bcl-xl, which resulted in increased apoptosis of 
tumor cells. 
4  Conclusions 
We investigated the mechanisms underlying the anti-tumor 
effects of five COS fractions. Our results demonstrated that 
COS inhibited the proliferation of A549 cells. COS6 also 
suppressed cyclin D1 and bcl-xl mRNA expression in these 
cells. We demonstrated that of the five fractions, COS6 was 
the most potent inhibitor of cell proliferation as well as cyclin 
D1 and bcl-xl mRNA levels. COS6-mediated anti-tumor ac-
tivity may be initiated via its binding with the cell surface 
receptor, or via endocytosis into the intracellular environ-
ment; however the exact mechanisms and signaling path-
ways underlying this function remain to be further eluci-
dated. 
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